Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
An African senior gentleman speaks with a clinician during a routine check-up in the doctor's office.
Black men are more likely than White men to be diagnosed with prostate cancer and two to four times more likely than other racial and ethnic groups to die from the disease.
iStock, FatCamera

Biomarkers for Prostate Cancer Risk in Black Men Identified

Genetic, molecular changes in Black men with diabetes and prostate cancer could be developed into a precise diagnostic tool

City of Hope
Published:Aug 16, 2023
|3 min read
Register for free to listen to this article
Listen with Speechify

LOS ANGELES, CA — City of Hope researchers have identified a cell metabolism process found in men with diabetes and metastatic prostate cancer that could one day lead to improved testing and treatments for Black men with these diseases. The research will be highlighted in the press program for the American Chemical Society (ACS) Fall 2023.

Black men are more than twice as likely than other men to die from prostate cancer. In a continued search to develop inclusive diagnostic and predictive tests and personalized treatments, the researchers conducted a small clinical trial that identified four metabolism-related biomarkers linked to an increased risk of metastatic prostate cancer in men of West African heritage.

“We have identified genetic and molecular changes that can be developed into a tool to predict which Black men are at the highest risk of developing metastatic prostate cancer,” said Sarah Shuck, PhD, principal investigator of the trial who will present the data at ACS. Shuck is an assistant professor at the Arthur Riggs Diabetes & Metabolism Institute and the Department of Diabetes & Cancer Metabolism at City of Hope, CA. “This test would give doctors the ability to more accurately predict patients’ prognoses and equip scientists with more data as they work to design therapies that prevent prostate cancer from developing in the first place.”

There lies the problem!

The problem appears to be the production of a highly reactive compound known as methylglyoxal (MG), a byproduct of metabolism that is elevated in people with diabetes. MG binds to DNA, RNA, and protein, creating a complex that may promote cancer emergence due to its instability and disrupted function.

Prostate cancer is the second most common cancer in men. Black men are 70 percent more likely than White men to be diagnosed with prostate cancer and two to four times more likely than other racial and ethnic groups to die from the disease, according to 2023 data from the American Cancer Society.

Diabetes is a chronic metabolic disease characterized by elevated levels of blood glucose or sugar, which over time leads to serious damage to the heart, blood vessels, eyes, kidneys, and nerves. Black adults are 60 percent more likely than White adults to be diagnosed with diabetes and twice as likely to die from diabetes, according to the most recent data available from the U.S. Department of Health and Human Services Office of Minority Health.

Shuck’s lab focuses on the study of how metabolic dysregulation causes diabetes and cancer. She and her colleagues investigate the biochemistry involved when excess sugar damages important molecules.

Is prostate cancer race-dependent? 

To see if the identified dysregulated complexes were linked to race and genetics, the team conducted a small clinical study where they gathered blood samples from 371 men with and without prostate cancer from across the nation. To determine race, they assessed samples for genetic evidence of West African heritage using methods developed by collaborators Rick Kittles, PhD, MS, and Leanne Woods-Burnham, PhD, who were at City of Hope when the research was conducted.

Next, the researchers, including John Termini, PhD, professor in the Department of Cancer Biology and Molecular Medicine at City of Hope, looked at four biomarkers associated with MG and the complexes it forms with DNA, RNA, and protein. The biomarkers also included variation in a gene, GLO1, that encodes a protein that detoxifies these complexes.

Surprisingly, the men of West African descent had fewer of these malignancy-promoting complexes in their blood. Contrary to expectations, a lower level of these complexes was linked to a greater risk of metastatic disease. 

The researchers hypothesize that, in men of West African descent, tumor cells sequester these complexes and spur metastatic processes from within. These findings did not apply to men of European descent. Going forward, City of Hope researchers intend to gain a better understanding of prostate cancer disparities in the hopes of developing a diagnostic test.

- This press release was originally published on the City of Hope website